Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood fat test may reveal hidden heart dangers after stent surgery

NCT ID NCT07197242

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether measuring a type of fat in the blood, called lipoprotein(a), can help predict future heart problems in people who have had a stent placed to open a blocked artery. Researchers will follow 156 adults for one year after their procedure to see if those with higher Lp(a) levels are more likely to have a heart attack or need another procedure. The goal is to improve how doctors assess heart risk, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

targeted cohort consists of men and women presenting with stable ischemic heart disease scheduled to undergo elective PCI at the Assiut University Heart Hospital cardiac catheterization unit. Eligible patients must provide informed consent and undergo baseline blood sampling. The study excludes patients with recent acute coronary syndrome (ACS within 30 days), cardiogenic shock, prior cardiac transplantation/LVAD, limited life expectancy from non-cardiac causes, or those enrolled in contemporary blinded clinical trials specifically for Lp(a)-lowering therapies. By selecting an elective CAD population, the study narrows focus to a lower baseline

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older Undergoing elective PCI for stable coronary artery disease Ability to provide informed consent Willingness to undergo blood sampling prior to PCI Exclusion Criteria: * Acute coronary syndrome within 30 days Cardiogenic shock Prior heart transplant or left ventricular assist device (LVAD) Life expectancy less than 1 year due to non-cardiac causes Participation in a blinded Lp(a)-lowering outcome trial at the time of enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.